The aim of this retrospective, multicenter study would be to extend the phenotypic spectrum of DeSanto Shinawi Syndrome and improve the knowledge of its evolution. To this end, the investigators would like to issue a call for international collaboration in order to create a series of new genetically diagnosed patients, not yet described in previous publications, and with a larger number of individuals evaluated in a single study. One of the aims would be to establish a set of standardized clinical and paraclinical examinations to be carried out at diagnosis and for follow-up of affected patients. This would enable patients, their families and the caregivers involved to better anticipate future management.
Main objective : Update clinical and paraclinical knowledge of DeSanto-Shinawi syndrome. Secondary objectives: * Inventory the clinical signs of the syndrome described to date and look for recurrence between patients. * Select a set of standardized clinical and paraclinical examinations for diagnosis. * Establish appropriate management and follow-up. * To compare the phenotype of patients with DESSH due to a pathogenic point variation in the WAC gene and those with a microdeletion involving the WAC gene. Main inclusion criteria: Children and adults of any age. Molecular diagnosis of a pathogenic variant involving the WAC gene (SNV, CNV, SV). Main non-inclusion criteria: Patients with a molecular diagnosis of another VP (SNV) of a gene responsible for a neurodevelopmental disorder. Patient having already participated in a DESSH study with published data. No patient data available. Primary endpoint: The data collected will enable the investigators to meet the objective, namely to expand clinical and paraclinical knowledge of DeSanto-Shinawi syndrome. Main secondary endpoints: NA (descriptive study) Statistics: NA (descriptive study)
Study Type
OBSERVATIONAL
Enrollment
50
Clermont-Ferrand University Hospital
Clermont-Ferrand, Auvergne, France
RECRUITINGClinical knowledge
Morphologic description with photos (optional) at a specified date (front and side of the face, hands-feet : plant and palm) using HPO terms
Time frame: Through study completion, an average of 2 years
Clinical knowledge
Overall clinical examination and interrogatory at the last medical consultation (neurologic, cardiologic, gastroenterologic, pulmonary, urinary, global development, etc.) : data collected using a redcap form.
Time frame: Through study completion, an average of 2 years
Clinical knowledge
Height, weight and head circumferance at birth and at last visit
Time frame: Through study completion, an average of 2 years
Paraclinical knowledge
Any psychometric scale performed during lifetime : Language delay, Motor delay, ADHD, IQ, ASD
Time frame: Through study completion, an average of 2 years
Paraclinical knowledge
Any exams performed during lifetime : EEG, neuroMRI, abdominal echography, cardiac echography
Time frame: Through study completion, an average of 2 years
Recurrence of clinical signs
Inventory the clinical signs of the syndrome described to date and mesure concordance or not
Time frame: Through study completion, an average of 2 years
Standardized examinations
Using concordance of signs, mesure the clinical and paraclinical necessary at diagnosis
Time frame: Through study completion, an average of 2 years
Management & Follow-up
Using concordance of signs at different ages, establish appropriate management and follow-up.
Time frame: Through study completion, an average of 2 years
Genotype phenotype correlation
Compare the phenotype of DESSH patients with pathogenic point variation in the WAC gene and those with microdeletion involving the WAC gene
Time frame: Through study completion, an average of 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.